Intellia Therapeutics, Inc. (NTLA) · Aug 6, 2026 · Company update

HAE remains on track, but ATTR safety findings temper the update

HAE remains on track, but ATTR safety findings temper the update

The headline HAE success is largely already known. The 87% attack reduction, 62% attack-free rate, favorable safety profile, and statistically significant Phase 3 HAELO results were disclosed in April and expanded in June, so this filing mainly confirms—not newly creates—the lonvo-z value case. The company still expects FDA BLA acceptance in the second half of 2026 and a U.S. launch in the first half of 2027 (HAE program update).

MetricQ2 2026Q2 2025Published expectation
Collaboration revenue$7.7 million (Financial Results)$14.2 million (Financial Results)~$15.1 million
Net loss per share$(0.80) (Income Statement)$(0.98) (Income Statement)$(0.86)
Net loss$(106.6) million (Income Statement)$(101.3) million (Income Statement)—
Cash, equivalents and marketable securities$628.4 million (Balance Sheet Data)$605.1 million at Dec. 31, 2025 (Balance Sheet Data)—

The quarterly numbers were mixed, with a large revenue shortfall offset by a modest EPS beat. Collaboration revenue fell to $7.7 million from $14.2 million and was well below the published consensus of roughly $15.1 million, primarily because Regeneron revenue declined. The $(0.80) per-share loss was slightly better than the roughly $(0.86) expectation, but that benefit is less important than the sharp revenue miss and does not change the company’s pre-commercial economics (Income Statement).

The most important new information is an ATTR safety risk that remains unresolved. A genomic review of more than 600 samples linked the highest liver transaminase elevations with one HLA allele, prompting HLA genotyping for current and future Phase 3 participants. Enrollment has resumed and MAGNITUDE-2 remains on track for completion in the second half of 2026, but the finding adds a new screening and regulatory issue to nex-z’s development path (Nex-z program update).

The balance sheet reduces near-term financing pressure, but mostly reflects the April capital raise. Cash increased to $628.4 million after approximately $195 million of net offering proceeds, and management says resources should fund operations into at least 2028, including beyond the planned lonvo-z launch. That is supportive, but it is not a new commercial milestone and comes with the usual dilution from the equity financing (Cash Position).

Net read: the filing preserves the lonvo-z launch story but adds enough ATTR uncertainty and revenue weakness to prevent a clean positive surprise. The HAE program is advancing on schedule, while the fresh HLA finding creates a meaningful—though not yet clearly program-threatening—risk around nex-z. With the strongest HAE data already public and no upgraded timeline or new financial upside, the overall update lands as mixed versus expectations.

Original filing on SEC EDGAR

More Intellia Therapeutics, Inc. news

HAE remains on track, but ATTR safety findings temper the update | NTLA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.